Arthritis, Rheumatoid
Conditions
Keywords
Rheumatoid Arthritis, Methotrexate, Tripterygium, TNF inhibitor
Brief summary
In this 24-week, multi-center, randomized, double-blind study, the investigators will evaluate the efficacy and safety profile of subcutaneously injected Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, combined with oral Tripterygium Wilfordii for patients with active rheumatoid arthritis.
Detailed description
This study evaluates the efficacy and safety of YISAIPU plus Tripterygium wilfordii (T2w) for the treatment of RA patients. YISAIPU is a recombinant human tumor necrosis factor receptor fusion protein, and tripterygium wilfordii is a chloroform/methanol extract of Tripterygium wilfordii Hook F. Objectives: 1. To compare the efficacy of YISAIPU plus T2w versus MTX monotherapy for the treatment of signs and symptoms of RA. 2. To evaluate the safety of YISAIPU plus T2w in patients with RA for 24 weeks. Design: This is a randomized, 24-week, double-blind, parallel group study, and 506 patients with active RA will be randomized in a 1:1:1:1 ratio to one of the following four parallel treatment arms: 1. Methotrexate monotherapy 2. T2w monotherapy 3. YISAIPU plus methotrexate 4. YISAIPU plus T2w Escape: On week 13, all participants with inadequate response, defined as a \<30% improvement of swollen and tender joint counts from baseline, will switch to YISAIPU plus T2w treatment throughout the study. Endpoints : 1. ACR20, ACR50 and ACR70 response rates at 12 and 24 weeks. 2. DAS 28 (CRP) and DAS 28 (ESR) at 12 and 24 weeks. 3. EULAR response rates at 12 and 24 weeks. 4. Health assessment questionnaire (HAQ) at 12 and 24 weeks. 5. Patient assessment of arthritis pain at 12 and 24 weeks. 6. Patient and physician global assessment of arthritis at 12 and 24 weeks.
Interventions
Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
DRUGMethotrexate
Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
DRUGYisaipu
Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-65 years with informed consent * Diagnosis of rheumatoid arthritis (according to 2010 ACR/EULAR classification criteria) * Disease duration \> 6 weeks * Swollen joint (SJC)≥4 and tender joint count(TJC)≥4 * ESR \>28 mm/hr or C-reactive protein \> 1.5 ULN * Positive RF or anti-CCP antibody on screening * Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA * No evidence of active or latent or inadequately treated Mycobacterium tuberculosis infection
Exclusion criteria
* Pregnant, lactating or further fertility requirements * Previously received any biologic agents. * Recently (\<12 weeks) received methotrexate, leflunomide, salazosulfapyridine, azathioprine, cyclosporine, mycophenolate mofetil or Tripterygium Wilfordii. * Active or chronic infection, including HIV, HCV, HBV, tuberculosis. * History of any other rheumatic autoimmune disease * History of any lymphoproliferative disorder * Malignancy or history of malignancy. * Abnormal laboratory tests, including: Hemoglobin \<8.5 g/dL, White blood cell count \<3.5 x 109/L, Platelet count \<100 x 109/L, AST/ALT \>1.5 ULN, and serum creatine \> 1.5 mg/dL. * Severe, progressive, or uncontrolled cardiac, pulmonary, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine or neurologic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The American College of Rheumatology 50 (ACR50) response at 12 weeks | week 12 | The difference of ACR50 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The American College of Rheumatology 20/70 (ACR20/ACR70) response at 12 weeks | week 12 | The difference of ACR20 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12. |
| The American College of Rheumatology 20/50/70 (ACR20/ACR50/ACR70) response at 24 weeks | week 24 | The difference of ACR20, ACR50 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 24. |
| The European League Against Rheumatism (EULAR) response at 12 weeks | week 12 | The difference of proportions of patients meeting EULAR response between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12. |
| Health Assessment Questionnaire without Didability Index (HAQ-DI) at 12 weeks | week 12 | The change in HAQ-DI score from baseline to week 12 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX). HAQ-DI is an index measuring the quality of life related to health, which includes 20 questions in terms of three categories: * from 0 to 1: mild difficulties to moderate disability, * from 1 to 2: disability moderate to severe, * from 2 to 3: severe to very severe disability. The mean score is recorded as the result. |
| The Disease Activity Score-28 (DAS28) response at 24 weeks | week 24 | The change in DAS28 score from baseline to week 24 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX). DAS28 ＝ 0.56\*SQRT(TJC28) + 0.28\*SQRT(SJC28) + 0.36\*ln(CRP + 1) + 0.014\*GH + 0.96 * TJC28: The number of tender joints (0-28). * SJC28: The number of swollen joints (0-28). * CRP: The C-Reactive Protein level (in mg/l). * GH: The patient global health assessment (from 0=best to 100=worst). The 28 joint: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees. |
Other
| Measure | Time frame | Description |
|---|---|---|
| The Incidence of adverse events during 24-week study | week 24 | Incidence of adverse events and sever adverse events (SAE), including hospitalized or Treatment-emergent adverse events, during 24-week study. |
Countries
China
Outcome results
None listed